This announcement is a separate document:
康寧傑瑞製藥-B：自願公告 - JSKN033用於治療HER2表達的晚期或轉移性實體瘤的I/II期臨床試驗在澳大利亞獲批
ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT - A PHASE I/II CLINICAL TRIAL OF JSKN033 FOR THE TREATMENT OF HER2-EXPRESSING ADVANCED OR METASTATIC SOLID TUMORS WAS APPROVED IN AUSTRALIA
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.